|
|
Volumn 138, Issue 15, 2018, Pages 1605-1607
|
|
Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial
a
|
|
Author keywords
Diabetes mellitus; Liraglutide
|
|
Indexed keywords
ANTIDIABETIC AGENT;
ANTILIPEMIC AGENT;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LIRAGLUTIDE;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PLACEBO;
BIOLOGICAL MARKER;
AGE;
ATHEROGENESIS;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CEREBROVASCULAR ACCIDENT;
CLINICAL OUTCOME;
CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE DURATION;
DRUG EFFICACY;
ESTIMATED GLOMERULAR FILTRATION RATE;
FOLLOW UP;
HEART DEATH;
HEART FAILURE;
HEART INFARCTION;
HEART MUSCLE REVASCULARIZATION;
HEART PROTECTION;
HIGH RISK PATIENT;
HOSPITALIZATION;
HUMAN;
LETTER;
MAJOR ADVERSE CARDIAC EVENT;
MAJOR CLINICAL STUDY;
MAXIMUM TOLERATED DOSE;
MORTALITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PATHOPHYSIOLOGY;
POST HOC ANALYSIS;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
RISK FACTOR;
SENSITIVITY ANALYSIS;
SEX;
SMOKING;
UNSTABLE ANGINA PECTORIS;
BLOOD;
DYSLIPIDEMIA;
MULTICENTER STUDY (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK ASSESSMENT;
TIME FACTOR;
TREATMENT OUTCOME;
BIOMARKERS;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, LDL;
DIABETES MELLITUS, TYPE 2;
DYSLIPIDEMIAS;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPOGLYCEMIC AGENTS;
LIRAGLUTIDE;
MULTICENTER STUDIES AS TOPIC;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
RISK FACTORS;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 85055606411
PISSN: 00097322
EISSN: 15244539
Source Type: Journal
DOI: 10.1161/CIRCULATIONAHA.118.036862 Document Type: Letter |
|
Times cited : (26)
|
|
References (5)
|
